Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

作者：John H. Strickler, Judith Raimbourg, Jonathan Cohen, François Ghiringhelli, Manish R. Sharma, Chiyoe Kitagawa, Ki Hyeong Lee, Bert H. O’Neil, Maria J. de Miguel, Esma Saada-Bouzid, Rui Li, Nandini Rudra-Ganguly, Adam Luo, Apurvasena Parikh, Gladys Morrison, Martha Neagu Aristide, Zoë Hunter, Michael C. Burns, Yasutoshi Kuboki · 年份：2026 · DOI：10.1158/1078-0432.33158532 · 研究领域：Medicine、Cancer research、Internal medicine

<p>Supplementary Figure S3. Cycle 1 PK (Cmax and AUC) comparisons for Temab-A conjugate and free Top1 inhibitor following 3-mg/kg Q3W dosing of Temab-A in Asian and non-Asian patients with GEA.</p>